Lewis H. Kuller and Oscar L. Lopez
Alzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901
Background The modern era of Alzheimers disease (AD) research began in the early 1980s with the establishment of AD research centers and expanded research programs at the National Institute on Aging. Methods Over the past 30 years, there has been success in defining criteria for AD and dementia, association of important genetic disorders related to premature dementia in families, the association of apolipoprotein-E4, and measurement of incidence and prevalence and selected risk factors. However, prevention and treatment have been elusive. Results The development of new technologies, especially magnetic resonance imaging, positron emission tomography to measure amyloid in vivo in the brain and glucose metabolism, cerebrospinal fluid examination, better genetic markers, large-scale longitudinal epidemiology studies, and preventive clinical trials has rapidly begun a new era of research that offers opportunities to better understand etiology, that is, determinants of amyloid biology in the brain, neurofibrillary tangles, synaptic loss, and dementia. Conclusions There are three major hypotheses related to dementia: amyloid deposition and secondary synaptic loss as a unique disease, vascular injury, and aging. New research must be hypothesis-driven and lead to testable approaches for treatment and prevention.
ASCI-ID: 285-165
Alzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on agingAlzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010
The epidemiology of Alzheimers disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Review of selected databases of longitudinal aging studiesAlzheimer`s & Dementia, 2012, 8(6), 584-589. DOI: 10.1016/j.jalz.2011.09.232
Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive declineAlzheimer`s & Dementia, 2013, 9(3), 318-325. DOI: 10.1016/j.jalz.2011.11.009
The Alzheimers Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnosesAlzheimer`s & Dementia, 2010, 6(2), 104-109. DOI: 10.1016/j.jalz.2009.12.005
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimers Association Research Roundtable WorkgroupAlzheimer`s & Dementia, 2011, 7(4), 367-385. DOI: 10.1016/j.jalz.2011.05.2351
Anesthesia in presymptomatic Alzheimers disease: A study using the triple-transgenic mouse modelAlzheimer`s & Dementia, 2011, 7(5), 521-531. DOI: 10.1016/j.jalz.2010.10.003
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Physician outpatient contacts and hospitalizations among cognitively impaired elderlyAlzheimer`s & Dementia, 2009, 5(1), 30-42. DOI: 10.1016/j.jalz.2008.05.2493
Dementia literacy: Recognition and beliefs on dementia of the Australian publicAlzheimer`s & Dementia, 2009, 5(1), 43-49. DOI: 10.1016/j.jalz.2008.03.011
Associations among measures of awareness of cognitive deficits in dementiaAlzheimer`s & Dementia, 2010, 6(4), 312-318. DOI: 10.1016/j.jalz.2009.06.005
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008Alzheimer`s & Dementia, 2009, 5(2), 85-92. DOI: 10.1016/j.jalz.2009.01.021
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on agingAlzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010
Commentary on `A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.` Establishing a national biomarker database: Utility and incentivesAlzheimer`s & Dementia, 2009, 5(2), 108-113. DOI: 10.1016/j.jalz.2009.01.015
Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Facilitating Alzheimer's disease drug development in the United StatesAlzheimer`s & Dementia, 2009, 5(2), 125-127. DOI: 10.1016/j.jalz.2009.01.005
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studiesAlzheimer`s & Dementia, 2009, 5(2), 128-129. DOI: 10.1016/j.jalz.2009.01.018
Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Alzheimer's disease translational research programs at the National Institute on AgingAlzheimer`s & Dementia, 2009, 5(2), 130-132.
Commentary on map for the prevention of dementia II: Leon Thal Symposium 2008. Big Asks”: What can be changed to increase and speed progress on Alzheimer's disease research and treatment?Alzheimer`s & Dementia, 2009, 5(2), 137-139. DOI: 10.1016/j.jalz.2009.01.003
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. A proposal to increase participation in Alzheimer's disease clinical trialsAlzheimer`s & Dementia, 2009, 5(2), 140-142. DOI: 10.1016/j.jalz.2009.01.004
Commentary on A roadmap for the prevention of dementia II. Leon Thal Symposium 2008. Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patientsAlzheimer`s & Dementia, 2009, 5(2), 143-146. DOI: 10.1016/j.jalz.2009.01.013
Commentary on A roadmap for the prevention of dementia II. Leon Thal Symposium 2008. Who may benefit from disease-modifying studies in Alzheimer's disease?Alzheimer`s & Dementia, 2009, 5(2), 147-148. DOI: 10.1016/j.jalz.2009.01.007
Commentary on A roadmap for the prevention of dementia II. Leon Thal Symposium 2008. Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and strokeAlzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012
Commentary on A roadmap for the prevention of dementia II. Leon Thal Symposium 2008. Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and strokeAlzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy importAlzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy importAlzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Comments from abroadAlzheimer`s & Dementia, 2009, 5(2), 157-158. DOI: 10.1016/j.jalz.2009.01.009
Commentary on A roadmap for the prevention of dementia II: Leon Thal symposium 2008. The megacommunity approach to Alzheimer's diseaseAlzheimer`s & Dementia, 2009, 5(2), 163-165. DOI: 10.1016/j.jalz.2009.02.002
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challengesAlzheimer`s & Dementia, 2009, 5(2), 166-171. DOI: 10.1016/j.jalz.2008.12.002
Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.A federally funded corporation for the prevention and treatment of cognitive impairment and brain agingAlzheimer`s & Dementia, 2009, 5(2), 172-179. DOI: 10.1016/j.jalz.2009.01.023
Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-oldAlzheimer`s & Dementia, 2009, 5(4), 318-323. DOI: 10.1016/j.jalz.2009.04.1230
Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whitesAlzheimer`s & Dementia, 2009, 5(6), 445-453. DOI: 10.1016/j.jalz.2009.04.1234
Closing the dementia care gap: Can referral to Alzheimer's Association chapters help?Alzheimer`s & Dementia, 2009, 5(6), 498-502. DOI: 10.1016/j.jalz.2009.01.024
Outcome over seven years of healthy adults with and without subjective cognitive impairmentAlzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002
White matter integrity and cortical metabolic associations in aging and dementiaAlzheimer`s & Dementia, 2010, 6(1), 54-62. DOI: 10.1016/j.jalz.2009.04.1228
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysisAlzheimer`s & Dementia, 2010, 6(1), 70-74. DOI: 10.1016/j.jalz.2009.04.1231
Early dementia diagnosis and the risk of suicide and euthanasiaAlzheimer`s & Dementia, 2010, 6(1), 75-82. DOI: 10.1016/j.jalz.2009.04.1229
The worldwide societal costs of dementia: Estimates for 2009Alzheimer`s & Dementia, 2010, 6(2), 98-103. DOI: 10.1016/j.jalz.2010.01.010
A European perspective on population studies of dementiaAlzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Counting dementia: There is no one best wayAlzheimer`s & Dementia, 2011, 7(1), 10-14. DOI: 10.1016/j.jalz.2010.11.003
Operationalizing diagnostic criteria for Alzheimers disease and other age-related cognitive impairmentPart 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimers disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participantsAlzheimer`s & Dementia, 2011, 7(4), 412-417. DOI: 10.1016/j.jalz.2010.08.234
How golden is the gold standard of neuropathology in dementia?Alzheimer`s & Dementia, 2011, 7(4), 486-489. DOI: 10.1016/j.jalz.2011.04.011
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimers disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimers disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Videoconference diagnosis and management of Choctaw Indian dementia patientsAlzheimer`s & Dementia, 2011, 7(6), 562-566. DOI: 10.1016/j.jalz.2011.02.006
Predictors of suicide in patients with dementiaAlzheimer`s & Dementia, 2011, 7(6), 567-573. DOI: 10.1016/j.jalz.2011.01.006
Functional deficits among patients with mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Psychosocial stress at work is associated with increased dementia risk in late lifeAlzheimer`s & Dementia, 2012, 8(2), 114-120. DOI: 10.1016/j.jalz.2011.03.001
The epidemiology of Alzheimers disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Some evolutionary perspectives on Alzheimers disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Analysis of case management programs for patients with dementia: A systematic reviewAlzheimer`s & Dementia, 2012, 8(5), 426-436. DOI: 10.1016/j.jalz.2011.06.004
Antihypertensive drug use and the risk of dementia in patients with diabetes mellitusAlzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414
Impact of the Food and Drug Administrations antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settingsAlzheimer`s & Dementia, 2012, 8(5), 453-457. DOI: 10.1016/j.jalz.2011.08.004
Predictive validity and diagnostic stability of mild cognitive impairment subtypesAlzheimer`s & Dementia, 2012, 8(6), 553-559.
Association of environmental tobacco smoke with dementia and Alzheimers disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Dementia and out-of-pocket spending on health care servicesAlzheimer`s & Dementia, 2013, 9(1), 19-29. DOI: 10.1016/j.jalz.2011.11.003
The global prevalence of dementia: A systematic review and metaanalysisAlzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007
Vascular disease and dementias: Paradigm shifts to drive research in new directionsAlzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care settingAlzheimer`s & Dementia, 2013, 9(2), 141-150. DOI: 10.1016/j.jalz.2012.09.011
Improving dementia care: The role of screening and detection of cognitive impairmentAlzheimer`s & Dementia, 2013, 9(2), 151-159. DOI: 10.1016/j.jalz.2012.08.008
A prediction model to calculate probability of Alzheimers disease using cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2013, 9(3), 262-268. DOI: 10.1016/j.jalz.2012.01.010
Mild cognitive impairment in a community sample: The Sydney Memory and Ageing StudyAlzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010
Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia StudyAlzheimer`s & Dementia, 2013, 9(4), 366-376. DOI: 10.1016/j.jalz.2011.12.009
Longterm anticholinergic use and the aging brainAlzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005
β-Site amyloid precursor proteincleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Risk of Alzheimer's disease incidence attributable to vascular disease in the populationAlzheimer`s & Dementia, 2011, 7(3), 356-360. DOI: 10.1016/j.jalz.2010.12.004
Mild cognitive impairment: Disparity of incidence and prevalence estimatesAlzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002
The epidemiology of Alzheimers disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-upAlzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005
No association between gain in body mass index across the life course and midlife cognitive function and cognitive reserveThe 1946 British birth cohort studyAlzheimer`s & Dementia, 2012, 8(6), 470-482. DOI: 10.1016/j.jalz.2011.09.228
The global prevalence of dementia: A systematic review and metaanalysisAlzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007
Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI StudyAlzheimer`s & Dementia, 2009, 5(3), 207-214. DOI: 10.1016/j.jalz.2009.01.027
Antihypertensive drug use and the risk of dementia in patients with diabetes mellitusAlzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimers disease and related disordersAlzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002
Vascular disease and dementias: Paradigm shifts to drive research in new directionsAlzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007